Employees: 44
Size Surrozen (SRZN) is a United States Health Care company (Biotechnology) with a market value of $605M, the 2550th largest of 3,085 United States companies the cockpit tracks. Shares closed at $31.74 on 18 Nov 2026.
Performance Over six months the shares gained 17.3%, against -25.6% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 192.1% over the last twelve months (peer median +13.3%); the operating margin is -485.4% (peer median -64.9%).
Valuation It trades at 48.5× enterprise value to sales against a peer median of 3.4× (2nd most expensive of 16).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $10.5M | $3.48M | $10.7M | $0 | $12.5M |
| Revenue growth | — | -67% | — | -100% | — |
| Gross profit | $10.3M | $2.94M | $9.21M | -$1.91M | $9.23M |
| EBITDA | -$50.9M | -$41.6M | -$24.1M | -$41.1M | -$41.1M |
| Net income | -$408M | -$242M | -$63.6M | -$43.0M | -$36.0M |
| Free cash flow | -$30.8M | -$30.4M | -$17.7M | -$40.8M | -$44.9M |
| Capital expenditure | $225,000 | $128,000 | $26,000 | $398,000 | $728,000 |
| Total debt | $5.84M | $6.64M | $8.47M | $3.38M | $5.60M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SRZN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.2% | -16.5% | 2nd highest of 21 |
| 6-month return | +17.3% | -25.6% | 4th highest of 20 |
| Distance from 52-week high | -16.1% | -48.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +192.1% | +13.3% | 4th highest of 17 |
| Operating margin | -485.4% | -64.9% | 4th lowest of 17 |
| EV / Sales | 48.5× | 3.4× | 2nd most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | 3.2× | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 11.0× | 39.8% | +143.5% |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | 2.2× | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |